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Francisella tularensis is a gram-negative pathogen that causes life-threatening infections in humans and has
potential for use as a biological weapon. The genetic basis of the F. tularensis virulence is poorly understood.
This study screened a total of 3,936 transposon mutants of the live vaccine strain for infection in a mouse model
of respiratory tularemia by signature-tagged mutagenesis. We identified 341 mutants attenuated for infection
in the lungs. The transposon disruptions were mapped to 95 different genes, virtually all of which are also
present in the genomes of other F. tularensis strains, including human pathogenic F. tularensis strain Schu S4.
A small subset of these attenuated mutants carried insertions in the genes encoding previously known virulence
factors, but the majority of the identified genes have not been previously linked to F. tularensis virulence.
Among these are genes encoding putative membrane proteins, proteins associated with stress responses,
metabolic proteins, transporter proteins, and proteins with unknown functions. Several attenuated mutants
contained disruptions in a putative capsule locus which partially resembles the poly--glutamate capsule
biosynthesis locus of Bacillus anthracis, the anthrax agent. Deletional mutation analysis confirmed that this
locus is essential for F. tularensis virulence.
Francisella tularensis is a gram-negative, facultative intracel-
lular bacterium that causes tularemia in humans and many
other species (53). F. tularensis is divided into four subspecies
or biotypes. F. tularensis subsp. tularensis (type A) and F. tu-
larensis subsp. holarctica (type B) are the types mostly associ-
ated with human disease. The infection is naturally transmitted
by multiple means, such as the bite of blood-sucking insects,
handling infected animal carcasses, consumption of contami-
nated food or water, or inhaling infectious aerosols. Disease
manifestation varies depending on the route of inoculation and
ranges from ulceroglandular infection (entry through skin) to
respiratory tularemia (inhalation). Among various forms of
tularemia, respiratory tularemia has attracted the most atten-
tion because it may cause high mortality (up to 35%) in hu-
mans in the absence of antibiotic therapy (48). In addition,
aerosolized F. tularensis can cause a large number of tula-
remia cases (11, 13). The infectious dose of F. tularensis in
humans via the airborne route is as low as 10 organisms (48).
F. tularensis was developed as a bioweapon by Japanese
germ warfare units during World War II and later by the
former Soviet Union and the United States because of its
extreme infectivity, high virulence, and ease of dissemina-
tion (16). F. tularensis is listed as a category A potential
agent of bioterrorism (16).
Despite the importance of this pathogen, the virulence
mechanisms of F. tularensis are poorly understood. The ill-
defined capsule (34, 60, 67), lipopolysaccharide (LPS) (61, 64,
74), and the genes involved in intramacrophage growth (42, 50,
69) are among a few known factors that can contribute to
pathogenesis and virulence of F. tularensis. The recently se-
quenced genomes of three F. tularensis strains have predicted
approximately 2,000 genes (40, 54), but many of the putative
genes do not have assigned biological roles. F. tularensis live
vaccine strain (LVS) is a type B derivative. LVS is relatively
avirulent in humans but causes a lethal infection in mice that
highly resembles human tularemia (2, 19). Thus, the mouse
infection model with LVS has been extensively used to study F.
tularensis pathogenesis and host response during tularemia.
The LVS genome has been fully sequenced (GenBank acces-
sion no. AM233362).
The lack of genetic manipulation tools has been a major
hurdle in understanding virulence determinants of this organ-
ism (53). Among the recent advancements in establishing ge-
netic tools in F. tularensis, a Tn5-based transposon-transposase
complex has been successfully used to generate random and
stable insertion mutations in the chromosome of F. tularensis
LVS (36). In this study, we have modified this mutagenesis
technique to perform a genome-wide screening to identify vir-
ulence determinants of F. tularensis LVS by signature-tagged
mutagenesis (STM). STM was originally developed to identify
virulence factors in Salmonella enterica serovar Typhimurium
by negative selection (33). This technique has been successfully
used to identify virulence-associated genes in many other
pathogens (10). Our STM screening work has led to the dis-
covery of 95 F. tularensis genes that contribute to the survival
of this pathogen in a mammalian host. Importantly, virtually all
identified genes from F. tularensis LVS are also present in the
genomes of other F. tularensis strains, including strain Schu S4
(40).
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MATERIALS AND METHODS
Bacterial strains and chemical reagents. F. tularensis LVS was kindly provided
by Karen Elkins. LVS and its derivatives were cultured with aeration in modified
Mueller-Hinton broth (MHB) supplemented with 0.025% ferric pyrophosphate
and IsoVitaleX (MHB) or on chocolate agar plates. When necessary, kanamycin
(10 g/ml) or hygromycin (200 g/ml) was included in the broth and agar media
for selection purposes. Escherichia coli strains DH5 and S17-1 were grown in
Luria-Bertani broth or on Luria-Bertani agar plates and, when appropriate,
ampicillin, kanamycin, and hygromycin were added to final concentrations of 100
g/ml, 50 g/ml, and 200 g/ml, respectively. All ingredients for bacterial culture
media and other chemicals used in this work were obtained from Sigma (St.
Louis, MO) unless otherwise stated.
Construction of tagged transposons. The Tn5-based EZ::TN transposon in the
pMOD3 plasmid (Epicenter, Madison, WI) was first modified by inserting a
kanamycin resistance cassette in the PstI/KpnI sites. The kanamycin resistance
cassette was amplified from the EZ::TN transposon (Epicenter) by PCR using
primers Pr451 (5-GGGTACCAAAGCCACGTTGTGTCTCAAA-3) and
Pr452 (5-GCTGCAGGTCGACTCTAGAGGAT-3). The resulting transposon
was individually tagged with distinct 52-bp oligonucleotides by inserting these
tags in the KpnI site of pMOD3. The tag sequences were amplified from the
pID701t plasmids by PCR using primers Pr455 (5-CAAGGTACCCATTCTAA
CCAAGCT-3) and Pr456 (5-GGGGTACCTACAACCTCAAGCT-3). These
tags were previously used to identify virulence determinants in Streptococcus
pneumoniae by the STM approach (41) and were generously provided by Sauli
Haataja. The sequences of the resulting transposon constructs were determined
by DNA sequencing using the primer Pr457 (5-ATTCAGGCTGCGCAACTG
T-3) based on the backbone sequence of pMOD3.
Construction of tagged mutants in F. tularensis strain LVS. The tagged trans-
posons were released from pMOD3 by restriction digestion with PvuII, separated
from the plasmid backbones in 1% agarose gels, and gel purified using the
QiaQuick gel extraction kit (QIAGEN, Valencia, CA). The isolated transposon
DNA fragments were mixed with the EZ::TN transposase (Epicenter) and in-
cubated to form transposome complexes at 20°C for 2 to 4 days according to
the supplier’s instructions. The complexes were electroporated into LVS under
the conditions described by Kawula et al. (36). The transformants were selected
on chocolate agar plates containing kanamycin (10 g/ml). The resulting colonies
were individually cultured in MHB and preserved in MHB containing 20%
(vol/vol) glycerol at 80°C for future characterization.
DNA electrophoresis and Southern hybridization. DNA cloning and manip-
ulations were carried out according to standard methods (59). F. tularensis
genomic DNA was prepared as described in “DNA sequencing and sequence
analysis,” below. For Southern hybridization with the STM strains, approxi-
mately 3 g chromosomal DNA from each strain was digested with EcoRI and
separated in a 1% agarose gel. All restriction enzymes and DNA standards used
in this study were purchased from New England Biolabs (Beverly, MA). DNA
was blotted to Hybond-N nylon membranes (GE Healthcare BioSciences
Corp., Piscataway, NJ) by the alkaline transfer method and hybridized with a
digoxigenin (DIG)-dUTP-labeled DNA probe essentially as described elsewhere
(45). The transposon-specific probe representing the 270-bp coding region of the
kanamycin resistance cassette in the transposon was amplified from the tagged
transposon with primers Pr626 (5-ATAAATGGGCTCGCGATAATGTC-3)
and Pr627 (5-GCGCATCAACAATATTTTCACCTG-3) and the PCR DIG
probe synthesis kit as described by the supplier (Roche, Indianapolis, IN). Sizes
of DNA fragments were estimated based on DIG-labeled DNA molecular weight
standards (Roche).
Selection of transposon mutants in mice. The tagged transposon mutants of
strain LVS were individually cultured overnight in MHB. The cultures were
centrifuged and resuspended to the same optical density at 600 nm (OD600) in
MHB. Equal volumes of the tagged mutants were pooled, supplemented with
sucrose to a final concentration of 10% (wt/vol), and stored at 80°C as the input
pools. The frozen stocks were later thawed in a 37°C water bath to determine the
concentration of viable bacteria. For mouse infection, the frozen stocks of the
STM pools with a predetermined concentration of viable bacteria were diluted to
approximately 1.25  105 CFU/ml with sterile phosphate-buffered saline (PBS)
for mouse infection.
Groups of four female BALB/c mice (6 to 8 weeks old; Taconic Farm, Ger-
mantown, NY) were each infected with a single-input pool by intranasal inocu-
lation of 40 l bacterial suspension (approximately 5,000 CFU). The mice were
anesthetized with ketamine-HCl (Fort Dodge Animal Health, Fort Dodge, IA)
and xylazine (Phoenix Scientific, St. Joseph, MO) in PBS immediately prior to
infection. Portions of the inocula were diluted in PBS and spread on chocolate
agar containing kanamycin (10 g/ml) to verify the infection dose and to gen-
erate a DNA template of the input pool for PCR detection. The mice were
sacrificed 7 days postinfection. The lungs, livers, and spleens were aseptically
removed and homogenized using tissue strainers (Becton Dickinson) and plugs
of 5-ml syringes. Each organ homogenate was diluted in 1 ml of sterile PBS and
partially plated (100 l of each homogenate) on chocolate agar containing
kanamycin (10 g/ml) to establish the output pool. The remaining portion of
each organ homogenate was stored at 80°C as a backup source of the output
pool. All animal infection procedures were in compliance with the guidelines of
the Institutional Animal Care and Use Committee.
Detection of recovered transposon mutants by PCR. The presence of the
tagged mutants in the input and output pools was detected by PCR essentially as
described elsewhere (43). All bacterial colonies obtained with each of the input
and output pools were washed off from agar plates with 5 ml sterile PBS. A
portion of the bacterial suspension (1.5 ml) was pelleted by centrifugation,
resuspended in 500 l H2O, boiled for 10 min to lyse the bacteria and liberate
chromosomal DNA, and centrifuged to remove bacterial debris. The superna-
tants were used as DNA templates for PCR detection of the STM strains in the
mutant pools. The remaining portion of the bacterial suspension was stored at
80°C as a backup source. Each input and output DNA template was tested in
41 PCRs, each of which contained a tag-specific primer and a common primer
based on the kanamycin resistance cassette of the transposon. The tag-specific
primers were synthesized based on our DNA sequence information for each of
the tags (41). To compare the amplification profiles of the input and output pools
for the same mutant sets, PCR products were separated in 1.2% agarose gels and
visualized by staining agarose gels with ethidium bromide (2 g/ml). An STM
strain was considered to be attenuated for infection when no or substantially
decreased PCR products were observed from the output pools of at least two
mice compared with a positive PCR signal for the corresponding input pools. To
avoid screening errors, strains with ambiguous results were rescreened in sepa-
rate infection experiments and sometimes in separate pools.
DNA sequencing and sequence analysis. Transposon insertion sites in the LVS
chromosome were determined by direct sequencing of genomic DNA using a
transposon-specific primer Pr800 (5-CGAGCCAATATGCGAGAACA-3) es-
sentially as described previously (55). Our experience suggested that the purity of
the genomic DNA preparations is vital for the success rate of DNA sequencing.
Briefly, a single STM strain was cultured in 10 ml MHB to an OD600 of 0.8 to 1.0,
pelleted by centrifugation, and resuspended in 567 ml TE buffer (0.01 M Tris-
HCl, pH 8.0, 1 mM EDTA). The bacteria were lysed by adding 40 l of 10%
sodium dodecyl sulfate and 40 l pronase (20 mg/ml) to the suspension and
incubating for 1 h at 37°C. After mixing with 100 l of 5 M NaCl, 80 l of 0.7 M
NaCl containing 10% (wt/vol) cetyltrimethylammonium bromide was added. The
mixtures were incubated for 10 min at 65°C before proceeding to the standard
phenol-chloroform extraction for final DNA purification (59). The purified
genomic DNA was used as a template for automated DNA sequencing. The
resulting DNA sequences were used to perform homology searches against the
complete genome sequences of F. tularensis strains LVS (accession no.
AM233362) and Schu S4 (40) (accession no. NC_006570). DNA and protein
sequence analyses were performed using DNASTAR Lasergene v6.1 for Macin-
tosh (Madison, WI).
In vitro growth index. The wild-type LVS and each of the attenuated mutants
identified in the STM screening were individually cultured overnight in MHB,
diluted to an OD600 of approximately 0.050 with fresh MHB, and allowed to grow
in the absence of antibiotic selection. The density of each culture was periodically
monitored by optical absorbance (OD600). The change of culture density for each
mutant strain was compared with that of LVS to assess potential defects of the
STM strains. The difference is expressed as the in vitro growth index (GI), which
is defined by the ratio between mutant density change and LVS density change
(mutant/wild type). The GI values at the 18-h time point are presented in Table 1,
because all tested strains were apparently in the late log growth phase at this
time, an optimal stage for detection of growth differences based on our experi-
ence. A GI value below or above 1 indicates the corresponding mutant had a
slower or faster growth rate, respectively, under these conditions. We observed
that F. tularensis mutants usually showed reproducible growth differences when
their in vitro GI values differed from that of the parent strain by more than 0.3
(unpublished data). We empirically used this cutoff value to define the growth
deficiency status of the STM strains.
Complementation of disrupted capB and capC. The wild-type capB and capC
genes were PCR amplified from the LVS genomic DNA using primer pairs Pr884
(5-AGACATATGACTACTTTGGATTTTTGGTTAATTG-3)/Pr1103 (5-TT
GTGTCATATGAAAACTCCTTTAAATACCGGATCCATATTTTCTCCTG
TTT-3) and Pr886 (5-AGACATATGGATCCGTTAACGCTCTCGATAGG-
3)/Pr1104 (5-TTGTGTCATATGAAAACTCCTTTAAATACTTATATTCCT
ACTATCTCAGGTCCAATTA-3), respectively. The PCR products were
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TABLE 1. F. tularensis LVS genes essential for lung infection identified by STM
Function group and









Cell surface structures and
membrane proteins
JS4512 FTL_0009 FTT1747 Outer membrane protein 1 0.70
JS3217 FTL_0073 FTT1676 Membrane protein 5 0.89
JS2802 FTL_0421 FTT0901 tul4 Lipoprotein, T-cell-stimulating antigen 2 0.89
JS4596 FTL_0540 FTT1568c lpxB Lipid A-disaccharide synthase 1 1.00
JS1430 FTL_0589 FTT1525c Hypothetical membrane protein 2 0.92
JS3023 FTL_0592 FTT1464c wbtA dTDP-glucose 4,6-dehydratase, LPS modification 1 0.74
JS2516 FTL_0597 FTT1459c wbtF NAD-dependent epimerase, LPS modification 2 0.70
JS4788 FTL_0645 FTT1416c Lipoprotein 2 0.81
JS2294 FTL_1096 FTT1103 Lipoprotein 2 0.78
JS1965 FTL_1134 NA Membrane protein 2 0.60
JS4709 FTL_1328 FTT0583 fopA Outer membrane-associated protein 5 0.49
JS1083 FTL_1354 FTT0759 Membrane protein 4 0.46
JS4622 FTL_1414 FTT0807 capA Transmembrane HSP60 family protein 2 1.10
JS2531 FTL_1415 FTT0806 capC Capsular polyglutamate biosynthesis protein
CapC
2 0.93
JS2512 FTL_1416 FTT0805 capB Capsular polyglutamate biosynthesis protein
CapB
3 1.21
JS1091 FTL_1475 FTT1314c Type IV pilus fiber building block protein 2 0.57
JS4638 FTL_1678 FTT0101 Membrane protein 1 0.61
Intracellular survival and
stress response
JS1967 FTL_0094 FTT1769C clpB Endopeptidase Clp ATP-binding chain B 5 0.46
JS2797 FTL_0111 FTT1359c iglA Intracellular growth 3 0.77
JS4621 FTL_0112 FTT1358c iglB Intracellular growth 2 0.96
JS3579 FTL_0113 FTT1357c iglC Intracellular growth 5 1.00
JS3200 FTL_0519 FTT1606 minD Division inhibitor ATPase 1 0.79
JS2866 FTL_0520 FTT1605 minC Septum site-determining protein 2 0.69
JS1816 FTL_0891 FTT0623 tig Molecular chaperone 5 0.43
JS2466 FTL_0892 FTT0624 clpP ATP-dependent Clp protease subunit P 1 0.90
JS2488 FTL_0893 FTT0625 clpX ATP-dependent Clp protease subunit X 2 0.72
JS1838 FTL_0894 FTT0626 lon ATP-dependent protease Lon 5 0.68
JS1216 FTL_1097 FTT1102 Macrophage infectivity potentiator 2 0.67
JS4549 FTL_1392 FTT1471c deaD Cold shock DEAD box protein A 4 0.64
JS4653 FTL_1473 FTT1312c uvrA DNA excision repair enzyme, subunit A 1 0.75
JS2712 FTL_1504 FTT0721c katG Catalase 2 0.70
Metabolism and biosynthesis
JS1849 FTL_0010 FTT1748 glpE Thiosulfate sulfurtransferase 1 0.95
JS2839 FTL_0193 FTT0283 cyoC Cytochrome O-ubiquinol oxidase subunit III 1 1.05
JS3158 FTL_0382 FTT0881c rocE Amino acid permease 2 0.39
JS4576 FTL_0387 FTT0884c aspC1 Aspartate aminotransferase 1 1.07
JS2511 FTL_0483 FTT0413c glgB 1,4--Glucan branching enzyme 1 0.93
JS2367 FTL_0485 FTT0415 glgC Glucose-1-phosphate adenylyltransferase 1 0.81
JS3699 FTL_0525 FTT1600c fumA Fumerate hydratase 2 0.56
JS2301 FTL_0584 FTT1530 fadB Acyl-CoA-binding protein 4 1.46
JS4239 FTL_0789 FTT1165c aspC2 Aspartate aminotransferase 5 0.71
JS4275 FTL_0846 FTT1117c Isochorismatase hydrolase family protein 1 0.62
JS4467 FTL_0960 FTT0684C sthA Soluble pyridine nucleotide transhydrogenase 5 0.89
JS1239 FTL_1240 FTT0963c aroG Phospho-2-dehydro-3-deoxyheptonate aldolase 5 0.34
JS2226 FTL_1266 FTT0941c lipP Lipase/esterase 1 0.89
JS2758 FTL_1273 FTT0936c bioF 8-Amino-7-oxononanoate synthase 1 0.77
JS2559 FTL_1274 FTT0935c bioC Biotin synthesis 1 0.95
JS4610 FTL_1275 FTT0934c bioD Dethiobiotin synthetase 5 0.90
JS2717 FTL_1419 FTT0802 cphB Cyanophycinase 1 0.90
JS2632 FTL_1553 FTT0504c sucC Succinyl-CoA synthetase beta chain 1 0.75
JS2228 FTL_1554 FTT0503c sucD Succinyl-CoA synthetase alpha chain 1 0.60
JS2292 FTL_1701 FTT1631c glpX Fructose-1,6-bisphosphatase 5 0.57
Transcription, translation,
and cell separation
JS3170 FTL_R0003 FTTr07 16S rRNA 16S rRNA 5 0.80
JS3560 FTL_R0004 FTTt19 tRNA-Ile tRNA-isoleucine 1 0.73
JS3583 FTL_0257 FTT0346 rpmJ 50S ribosomal protein L36 1 0.41
Continued on following page
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cloned in the NdeI site of the E. coli-Francisella shuttle plasmid pMP633 (44).
capB and capC were inserted between the ATG start and second codon of the
hygromycin resistance gene, resulting in plasmid pST1032 and pST1033. To
compensate the loss of a ribosome binding site and translational start codon, a
17-bp 5 noncoding sequence of the F. tularensis fopA gene (5-GTATTTAAA
GGAGTTTT-3) was added to the reverse primers Pr1103 and Pr1104. This
configuration allowed the Francisella groEL promoter to drive capB (or capC)
and the hygromycin resistance gene. Because the hygromycin resistance gene
solely relied on the added ribosome binding site at the 3 end of the capB or capC
insert for translation, only one orientation of the cloned PCR products was identified
in hygromycin-resistant E. coli clones. This configuration also ensured the expression
of the cap genes due to selection for hygromycin resistance. The sequences of the
complementation constructs were confirmed by DNA sequencing. pST1032 and
pST1033 were electroporated into the capB and capC mutants JS2512 and JS2531,
respectively, and used to infect BALB/c mice as indicated below.
Site-specific mutagenesis in F. tularensis. The capB, capC, and capA genes
were deleted in LVS by allelic replacement and counterselection using conjuga-
tive plasmid pDMK as described elsewhere (29). pDMK also carries the Tn5
TABLE 1—Continued
Function group and









JS4647 FTL_0428 FTT0908 parB Chromosome partition protein B 1 0.74
JS3754 FTL_0456 FTT0390c rpsU1 30S ribosomal protein S21 1 0.79
JS2299 FTL_0616 FTT1442c rpoA2 DNA-directed RNA polymerase,  subunit 1 0.50
JS4292 FTL_0768 FTT1179 bipA GTP-binding translational elongation factor Tu
and G family protein
1 0.84
JS3069 FTL_0899 FTT0631 hflX Protease, GTP-binding subunit 1 0.77
JS3240 FTL_0903 FTT0633 hflK Protease modulator 1 0.59
JS3165 FTL_0928 FTT0654 elbB DJ-1/PfpI family protein 3 0.90
JS3181 FTL_0950 FTT0675 rplY 50S ribosomal protein L25 3 0.90
JS4305 FTL_1030 FTT1056c rluB Ribosomal large subunit pseudouridine
synthase B
1 0.59
JS4451 FTL_1393 FTT1472c ppiC Peptidyl-prolyl cis-trans isomerase or parvulin 1 1.05
JS3773 FTL_1404 FTT0820 rplT 50S ribosomal protein L20 1 0.47
JS3636 FTL_1452 FTT0773 rpmA 50S ribosomal protein L27 1 0.67
JS2817 FTL_1461 FTT0766 deoD Purine nucleoside phosphorylase 1 0.20
JS2840 FTL_1474 FTT1314c greA Transcription elongation factor 5 0.43
JS1379 FTL_1601 FTT0463 yibK tRNA/rRNA methyltransferase 1 1.00
JS3633 FTL_1912 FTT0183c rpsA 30S ribosomal protein S1 1 0.46
Substrate binding/transport
JS4252 FTL_0133 FTT0249 feoB Ferrous iron transport protein 1 1.0
JS2678 FTL_0617 FTT1441 bfr Bacterioferritin 2 0.95
JS3451 FTL_0837 FTT1125 metQ D-Methionine-binding transport protein 1 0.68
JS3166 FTL_1233 FTT0968c Amino acid antiporter 1 0.69
JS4295 FTL_1458 FTT0769 secA Preprotein translocase, subunit A 1 0.83
JS1673 FTL_1528 FTT0708 Major facilitator superfamily transport protein 2 0.34
JS4666 FTL_1622 FTT0444 Multidrug transporter 1 1.06
JS4221 FTL_1672 FTT0105c Transporter AcrB/AcrD/AcrF family 1 0.71
JS1500 FTL_1750 FTT0138 secE Preprotein translocase, subunit E 1 0.79
JS3225 FTL_1936 FTT0209c Periplasmic solute-binding family protein 1 0.90
JS3948 FTL_1947 FTT1782c yjjk ABC transporter ATP-binding protein 2 0.50
Others
JS4680 FTL_0012 FTT1750 recA Recombinase A protein 1 0.83
JS3972 FTL_0337 FTT0843 Unknown 1 1.00
JS1488 FTL_0430 FTT0910 Unknown 4 0.66
JS1048 FTL_0439 FTT0918 Unknown 5 1.24
JS3952 FTL_0440 FTT0920 Transposase 1 0.95
JS3638 FTL_0514 FTT1611 Unknown 1 0.84
JS4714 FTL_0663 FTT1400c Unknown 1 0.70
JS4635 FTL_0723 FTT1221 Unknown 1 0.57
JS3434 FTL_0803 FTT1152 Unknown 2 0.78
JS1020 FTL_1075 FTT1015 Unknown 1 0.71
JS4619 FTL_1225 FTT0975 Unknown 1 0.94
JS3599 FTL_1623 FTT0443 Unknown 1 0.74
JS2308 FTL_1832 FTT0029c Unknown 1 0.61
JS4698 FTL_1867 FTT1726 yegQ Protease 1 1.06
a A single mutant for each ORF is shown when multiple independent mutants were identified for the ORF.
b The ORF designations are adopted from the annotations of the LVS genome (accession no. AM233362). For the genes with multiple alleles (the iglABC and 16S
rRNA genes), the precise alleles with transposon interruption were not determined. Only one of the possible insertion sites is listed.
c The ORF designations are adopted from the annotations of the Schu S4 genome (accession no. NC_006570). NA indicates the absence of the LVS ORF ortholog
in the Schu4 genome.
d The gene designations and functions are adopted from the annotated genome sequences of LVS (accession no. AM233362) and Schu S4 (accession no. NC_006570).
CoA, coenzyme A.
e Independent mutants with insertions at different positions of each ORF.
f The in vitro GI was calculated based on changes in the OD600 of each culture within the first 18 h of cultivation as described in Materials and Methods.
3092 SU ET AL. INFECT. IMMUN.
kanamycin resistance marker and the Bacillus subtilis sacB gene, a counterselec-
tion marker (25), and was generously provided by Anders Sjostedt. A 1.1-kb
DNA fragment upstream of the capB gene (including the 29-bp 5 capB coding
region) was amplified from LVS chromosomal DNA by PCR using primers
Pr890 (5-GGCGAGCTCTTGATGGGACCTATAGGCAGTGTG-3) and
Pr891 (5-ATCCTGAATTCAATTAACCAAAAATCCAAAGTAGTCA-3).
This 5-flanking region was cloned into SacI- and EcoRI-digested pBluescript II
SK() (Stratagene, La Jolla, CA) in E. coli D5, resulting in plasmid pST933.
The 3-flanking sequence, including the last 82 bp of the capA coding region, was
amplified with primers Pr892 (5-ATCCTGAATTCTTACTTGTTATCGATAT
TAGTTTAGTAG-3) and Pr893 (5-CTTGTCTCGAGATCTTTGTAATGCT
TTGTCAGTTT-3). The high-fidelity DyNAzyme EXT DNA polymerase (New
England Biolabs) was used for all PCR amplifications to minimize sequence
errors. The 3-flanking PCR product was cloned into the EcoRI/XhoI site of
pBluescript II SK(), resulting in plasmid pST934. To link the up- and down-
stream sequences, the insert DNA of pST934 was subcloned into the EcoRI/
XhoI site of pST933, and the resulting final plasmid was designated pST935.
Finally, the insert sequence in pST935 was moved into SacI/XhoI-digested
pDMK, resulting in the plasmid pDMK::capLVS or pST937.
pST937 was verified by DNA sequencing, transferred to E. coli S17-1, and used
to perform conjugation with LVS as described elsewhere (29). The conjugation
mixtures were first plated onto chocolate agar containing 100 g/ml of polymyxin
B for counterselection of the donor E. coli strain and 10 g/ml kanamycin for
selection of LVS transformants carrying the pST937 plasmid on the chromo-
some. To generate deletional mutants in the capBCA locus, the kanamycin-
resistant transformants were streaked on chocolate agar plates containing 5%
(wt/vol) sucrose. The sucrose-resistant colonies were further screened for the loss
of kanamycin resistance. The resulting clones were examined for the capBCA
deletion by PCR using two capBCA-flanking primers, Pr896 (5-AGCTGCACC
TGAGTTATTTGAT-3) and Pr903 (5-TCCCCTGAGCTTCTAACTTGA-3).
Correct deletion in the capBCA locus was further verified by DNA sequencing of
the PCR products from the positive clones. Clone ST938 was selected for further
characterization.
Mouse infection with attenuated LVS mutants. For competitive infection, the
wild-type LVS and each of the attenuated mutants were separately cultured
overnight in MHB, diluted to approximately 4  105 CFU/ml with sterile PBS,
and thoroughly mixed at a 1:1 ratio. The mixtures (40 l each, 	16,000 CFU)
were used to infect groups of three BALB/c mice by intranasal inoculation as
described above. Portions of the same mixtures were diluted with PBS and plated
on chocolate agar plates in the presence or absence of kanamycin (10 g/ml) to
determine the actual infection doses. Only the mutants were expected to grow on
the kanamycin-containing plates. The mice were sacrificed 7 days postinfection
to harvest the lungs, livers, and spleens. The organs were homogenized, serially
diluted with PBS, and plated on chocolate agar dishes to determine the viable
bacterial levels as described above. The level of attenuation is expressed as the
competitive index (CI), which is defined as the output ratio (mutant/wild type)
divided by the input ratio (mutant/wild type). The data are also expressed as the
fold change of attenuation by dividing the CFU values of the recovered mutants
by those of LVS.
The infection experiments with the complemented capBC insertion mutants
and capBCA deletion mutant were performed in a similar manner. BALB/c mice
were intranasally infected with doses as indicated in the figure legends for Fig. 3
and 4, below. Mice were sacrificed 7 days later to determine bacterial levels in the
lungs, livers, and spleens as described above.
RESULTS
Construction of tagged mutants in F. tularensis strain LVS.
As illustrated in Fig. 1A, tagged mutants were generated in F.
tularensis LVS using a derivative of the Tn5-based EZ::TN
transposon (36). A series of signature-tagged transposons were
generated by insertion of unique 52-bp tag sequences as de-
scribed in Materials and Methods. Each of the tagged trans-
posons was used to generate insertion mutants in LVS by
electroporation as described elsewhere (36). Our Southern
blot analysis of selected transposon mutants indicated that the
tagged transposons inserted into the chromosome of F. tula-
rensis LVS in a highly random manner (Fig. 1B). Mutants were
assembled into sets of 41, each with a unique tag, for further
screening in mice.
Establishment of lung infection screening model in mice. A
key requirement for successful STM screening is the ability to
recover sufficient numbers of inoculated bacteria from live
animals postinfection to allow the identification of each rep-
resentative mutant that survives within the mutant pool (10).
To this end, it is critical to select an appropriate animal model
and adequate parameters that includes infection route, dose,
and duration of infection time. We initially assessed the feasi-
bility of a mouse infection model for our STM screening.
Various laboratory mouse strains have been successfully used
to study respiratory infection of F. tularensis (20). Consistent
with previous reports (18, 22), our preliminary experiments
FIG. 1. Construction of STM strains in LVS by transposon mutagenesis. (A) The 52-bp oligonucleotide tags were separately cloned in the
KpnI-digested EZ::TN transposon as marked by inverted repeats (IR). The tagged transposon was liberated by digestion with PvuII and mixed with
EZ::TN transposase to form a transposome for transformation into LVS. The kanamycin-resistant transformants were sorted into various sets
based on the sequence identity of the tag in each of the transposons. (B) Detection of transposons in STM strains. A DNA blot representing 10
STM strains was probed with a 270-bp probe representing the kanamycin resistance cassette (Kanr) of the tagged transposon. The molecular sizes
of DNA markers are marked in bases.
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indicated that, among commonly used mouse strains, BALB/c
mice are relatively resistant to respiratory infection with LVS.
BALB/c mice were able to survive intranasal infection with 5 
103 CFU of LVS in the first week of infection (data not shown).
This resistance level allowed relatively large infection doses of
the mutant pools, thereby maximizing the representation of
each mutant in the pools. To test the feasibility of the BALB/c
mouse model, we performed infection experiments with a pool
of 41 STM strains via intranasal inoculation at various infec-
tion doses (103 to 104 CFU) (Fig. 2A). At various time points
following inoculation, pairs of mice were euthanized to deter-
mine the number of CFU in the lungs of each mouse. An
infection dose of 5  103 CFU resulted in minimal mortality in
the first 7 days of infection while allowing consistent recovery
of all inoculated STM strains from the lungs of multiple in-
fected mice except for those truly “attenuated” mutants (see
the next section for screening procedures). These infection
conditions were applied in screening the rest of the STM pools.
Selection and screening of attenuated mutants. A total of 96
sets of 41 mutants, totaling 3,936 strains, were screened in the
BALB/c mouse model of respiratory tularemia as described
above. We typically recovered thousands of bacterial colonies
from the lungs of each infected mouse. In contrast, the colo-
nies recovered from liver and spleen samples were much less
numerous and were highly variable from mouse to mouse un-
der the same conditions. For these reasons, we focused our
STM screening on the bacteria recovered from the lungs.
When the tissue lysates yielded relatively low numbers of bac-
terial colonies (
500 CFU), the PCR results became inconsis-
tent among animals infected with the same input pools (un-
published observation). We therefore repeated all infection
experiments that either yielded low numbers of bacterial col-
onies in the output pools or the highly contaminated output
colonies as assessed by colony size and morphology.
The presence or absence of individual mutants in the input
and output pools was detected by PCR using tag-specific prim-
ers. This screening procedure identified 341 strains that were
completely missing or substantially underrepresented in the
PCR profiles, representing 8.7% of the total strains screened.
These strains are referred to as attenuated mutants hereafter.
The proportion of the attenuated mutants identified in this
screening is within the range (5 to 15%) of previous studies
with other pathogens (10). Transposon insertion sites on the
chromosomes of these attenuated mutants were mapped by
DNA sequencing of the genome-transposon junctions. Se-
quence analyses localized the transposon insertion sites in 95
LVS genes, representing 4.8% of the 1,968 predicted open
reading frames (ORFs) in the LVS genome (accession no.
AM233362). The identified genes have been assigned into six
FIG. 2. Negative screening of the STM pools in mice. Each mutant in a single set was grown separately to an OD600 of 0.35 to prepare the input
mutant pool. The pool was used to infect four BALB/c mice by intranasal inoculation. The mice were sacrificed 7 days postinfection to remove
the lungs and recover the bacteria (output). The input and output pools of the same mutant sets were compared by amplifying the transposon with
tag-specific primers and detection by agarose gel electrophoresis. The mutants that were missing in the output pools from multiple mice infected
with the same input pools are indicated with asterisks.
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functional groups according to available information from ex-
perimental studies and sequence-based predictions (Table 1).
Except for FTL_1134 and FTL_0439, all of the genes iden-
tified in LVS are present in the fully sequenced genomes of
other F. tularensis strains, including OSU18 (type B) (54) and
Schu S4 (type A) (40). Some of the genes identified in this
study have been previously implicated as virulence determi-
nants of F. tularensis by other investigators, including minD (1),
clpB (31), the intracellular growth locus (iglA, iglB, and iglC)
(31, 39, 63), and the LPS O-antigen biosynthesis locus (wbtA
and wbtF) (12, 56, 72). However, the majority of these genes
represent novel bacterial factors that have not been previously
associated with F. tularensis virulence.
To help interpret the in vivo screening results, we also de-
termined the growth rate of the mutants that represented each
of the 95 identified genes. As listed in Table 1, the in vitro
growth index values for the majority of these representative
mutants are around 1, thus demonstrating that the transposon
insertions in the represented genes had little or no effect on the
in vitro growth of the LVS derivatives. A small subset of the
mutants showed various levels of growth defect as exemplified
by the mutants of FTL_1328 (fopA), FTL_0094 (clpB),
FTL_0891 (tig), and FTL_0382 (rocE). It is possible that the
growth defects contributed to the attenuation phenotype of
these mutants. Many of the identified genes were represented
by multiple independent mutants with disruptions in different
locations, therefore confirming the reproducibility of this STM
screening.
Verification of infection-defective status of selected mutants.
To determine the level of attenuation quantitatively, selected
mutants from different functional groups were used in coinfec-
tion experiments with the wild-type strain. Each of the chosen
mutants was mixed with the wild-type LVS in a 1:1 ratio and
used to infect mice via intranasal inoculation. As listed in
Table 2, all of the mutants tested were attenuated to various
extents in terms of their ability to replicate and survive in the
lungs. Growth defects observed in vitro might have contributed
to the attenuation phenotypes for some of the mutants
(JS1967-clpB, JS1838-lon, JS1415-aroG, JS4709-fopA, and
JS2840-greA). The rest of the tested mutants had no apparent
in vitro growth defect. The decreased survival of these mutants
in the lungs of mice was due to their defective growth in vivo
and/or increased susceptibility to innate immune mechanisms
of the host.
The iglC mutant JS3579 had the least reduction (sixfold) in
the ability to survive in the lungs, whereas the mutants repre-
senting sthA (JS4467), capB (JS2512), and capC (JS2531) were
undetectable at the end of the coinfection experiments. JS3579
carried an insertion immediately after the 162nd nucleotide of
the iglC-coding sequence. iglC is the third gene in the intracel-
lular growth locus operon (iglABCD), which is required for
intracellular survival of F. tularensis (31, 39, 63). There are two
copies of the iglABCD operon in the LVS genome as a part of
the pathogenicity island (29). Since the transposon appeared to
insert into one of the two iglC loci, the result suggests that two
copies of the iglABCD operon are necessary for efficient
growth of F. tularensis in vivo. Consistent with this notion,
multiple mutants with insertions in iglA and iglB of the same
operon were also attenuated (Table 1). Interestingly, Golov-
liov et al. showed that deleting one of the iglC genes did not
affect the ability of LVS to grow in mouse J774.1 macrophages
or mouse peritoneal exudate cells (29). We believe that the
lack of functional IglC was responsible for the attenuation
phenotype. However, it is also possible that a truncated form of
IglC might act as a dominant negative protein in mutant
JS3579 if the remaining 54 amino acids at its amino terminus
possessed an inhibitory activity on the other wild-type IglC
allele of the same chromosome.
As a part of our efforts to verify the attenuation status of the
mutants identified in this STM screening, we also tested strain
JS4467 in the category of metabolism and biosynthesis, be-
cause it did not show a significant in vitro growth defect (Table
1). Strain JS4467 carried a transposon disruption between nu-
cleotides 58 and 59 in the sthA-coding region. sthA encodes an
uncharacterized soluble pyridine nucleotide transhydrogenase
involved in the conversion of NADPH generated by peripheral
catabolic pathways to NADH, which can enter the respiratory
pathway for energy production. The in vivo survival deficiency
in strain JS4467 was therefore likely due to impaired energy
generation.
Strain JS1967, with a transposon insertion at the 3 region of
clpB, showed a severe deficiency (5,556-fold reduction) in this
lung infection model. Gray et al. first showed that the clpB
gene is required for intracellular growth of F. tularensis subsp.
novicida in the murine macrophage line J774.1 (31). This find-
ing was recently confirmed by an independent mutant
screening study of F. tularensis subsp. novicida with the
murine macrophage line RAW (71). ClpB, a highly con-
served ATP-dependent protease, participates in solubiliza-
tion and refolding of aggregated proteins, especially when the
organisms experience stress conditions, such as high tempera-
tures and oxidative pressure (28). The attenuation phenotype
of strain JS1967 might be caused by the impaired capability of
intracellular survival and/or replication due to the lack of the
ClpB chaperone function. Along the same line, strain JS1838,
with a disruption immediately after the translational start











JS1967 FTL_0094 clpB 0.00018  0.00015 5,556 31, 71
JS3579 FTL_0113 iglC 0.18240  0.18538 6 31, 39, 63
JS2788 FTL_0439 0 AV
JS3200 FTL_0519 minD 0.00556  0.00769 180 1
JS1838 FTL_0894 lon 0.00200  0.00191 500
JS4467 FTL_0960 sthA 0 AV
JS1415 FTL_1240 aroG 0 AV
JS4709 FTL_1328 fopA 0.00008  0.00105 12,500 23, 49, 71
JS4622 FTL_1414 capA 0.00001  0.00001 100,000
JS2531 FTL_1415 capC 0 AV
JS2512 FTL_1416 capB 0 AV
JS2840 FTL_1474 greA 0.00024  0.00015 4,167
a The same representative mutant of each gene as listed in Table 1 was chosen
to perform the coinfection analysis in mice.
b The gene designations are adopted from the annotations of the LVS and
Schu S4 genomes.
c In vivo CI for each mutant represents the mean  standard error of the CFU
values obtained from the lungs of the three mice infected with the same mutant–
wild-type mixture as described in Materials and Methods.
d Fold attenuation represents the reciprocal of the in vivo CI. AV, only the
parent strain LVS was detected in the lungs of the mice coinfected with the
LVS-mutant mixture.
e Relevant publications for F. tularensis are indicated.
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codon of lon, also exhibited 500-fold reduction in the capacity
of in vivo growth. The Lon and Clp proteins are stress-induced
ATP-dependent proteases that are responsible for removing
stress-damaged proteins in bacteria (47). lon is the last gene in
an apparent operon with tig (the trigger factor Tig), clpP (pro-
tease subunit ClpP of the ClpXP protease), and clpX (ATPase
subunit ClpX of the ClpXP protease). While the trigger factor
is involved in folding of newly synthesized proteins (17), the
ClpXP protease is involved in ClpB-independent proteolysis
(6). Interestingly, multiple attenuated mutants were also iden-
tified in tig, clpP, and clpX (Table 1), indicating that protein
folding and degradation by these proteases are critical for the
in vivo lifestyle of F. tularensis.
Mutant JS3200, with a disruption in the 3 region of minD,
showed a 180-fold reduction in in vivo survival. MinD is a
highly conserved septum site-determining protein along with
MinC and MinE. A MinD-deficient mutant of F. tularensis
subsp. novicida was found to be avirulent in mice and sensitive
to serum and oxidative killing (1). In Escherichia coli, MinD
controls the site of mid-cell division by recruiting MinC and
MinE to form the membrane-associated polar zone and the
MinE ring (58). In agreement with this result, two independent
mutants were also identified in minC (Table 1). minC, minD,
and minE are organized as an apparent operon with five ad-
ditional genes. These data suggest that appropriate bacterial
division is essential for in vivo growth and virulence of multiple
F. tularensis subspecies.
Strain JS4709, carrying an insertion in the 5 region of fopA,
was attenuated by 4 orders of magnitude in the coinfection
experiments (Table 2). FopA was originally identified as a
heat-modifiable protein in F. tularensis subsp. novicida (49).
Tempel et al. (71) recently showed that the fopA mutants of F.
tularensis subsp. novicida are deficient in growing in the murine
macrophages. Sequence analysis suggested that fopA is not a
part of any operon structure with its adjacent genes based on
the length of the intergenic regions and the gene direction.
Finally, we confirmed the attenuation phenotype of mutant
JS2840, which contained an insertion in the 3 region of greA.
Compared with the parent LVS strain, JS2840 was attenuated
by 4,167-fold in the coinfection experiments (Table 2). GreA
acts as a transcriptional elongation factor in E. coli by promot-
ing the transcription of certain genes through suppressing the
pausing and arrest of the RNA polymerase (5). E. coli cells
lacking both GreA and GreB (another transcriptional elonga-
tion factor) are hypersensitive to temperature changes (52).
GreA was found to be essential for Yersinia pestis virulence in
a subcutaneously infected mouse model (21). GreA appears to
be the only transcriptional elongation factor in F. tularensis,
because an extensive search of multiple F. tularensis genomes
did not identify a GreB homolog. greA appears to be a part of
a multigene operon along with FTL_1477 (thiamine pyrophospho-
kinase), FTL_1476 or pgi (glucose-6-phosphate isomerase),
FTL_1475 (type IV pilus fiber building block protein), and
FTL_1473 or uvrA (DNA excision repair enzyme, subunit A of
the UvrABC system). Interestingly, mutants JS4653 and
JS1091 with insertions in FTL_1475 and FTL_1473, respec-
tively, were among the attenuated strains identified in this
screening (Table 1).
Polar effect of the transposon. A large number of the iden-
tified genes are members of apparent operon clusters, raising
the possibility that the attenuation phenotypes for some of the
mutants could be due to a polar effect on the downstream
genes. We chose to assess this issue with the transposon inser-
tion strains in the gene locus of FTL_1416, FTL_1415, and
FTL_1414. Based on the sequence similarity of these genes to
the capsule biosynthesis genes of other bacteria (see the next
section), we have designated FTL_1416, FTL_1415, and
FTL_1414 as capB, capC, and capA, respectively. As illustrated
in Fig. 3, the capBCA genes are separated with short intergenic
sequences. Our preliminary reverse transcriptase PCR analysis
suggested that the capBCA genes are cotranscribed (unpub-
lished observation).
We reasoned that the transposon mutants in capB or capC
could not be complemented if the observed attenuation in
these mutants were due to a polar effect on the downstream
capA gene. The wild-type capB and capC were individually
cloned into shuttle vector pMP633 (44). As shown in Fig. 3, in
trans expression of the intact capC in the transposon mutant
JS2531 (capC) provided significant complementation of the
survival defect of the mutant in the lungs of BALB/c mice 7
days after intranasal inoculation. It should be noted that the
capB-complemented strains JS2512 (capB insertion mutant)
barely missed the significance cutoff (P 
 0.05) due to a large
intergroup variation in the mice infected with this strain, but
the trend was similar to that of the capC-complemented mu-
tant JS2531. These findings show that the observed attenuation
phenotypes with the capB and capC insertion mutants were at
least in part due to mutations in capB and capC. Thus, the
complementation experiments suggest that the transposon may
not block transcriptional read-through into the downstream
genes. It should be noted that, in both of the complemented
strains, the values were still over 10-fold less than the wild-type
value. These differences could be caused by multiple possibil-
ities, such as instability of the shuttle plasmid during infection,
inappropriate in trans expression levels of the CapB and CapC
proteins, and a partial polar effect.
Requirement of the putative capsule genes for infection.
Among the attenuated strains are those with disruptions in the
putative capsule biosynthetic capBCA genes (Table 1). At the
amino acid level, FTL_1416 and FTL_1415 share 38% and
29% sequence homology with the CapB and CapC of Bacillus
anthracis, respectively. CapB and CapC, together with CapA,
CapD, and CapE in B. anthracis, are responsible for the bio-
synthesis of the capsule. Unlike common polysaccharide-based
capsules in the vast majority of bacterial species, the B. anthra-
cis capsule is composed of poly--D-glutamic acids (PGA) (8).
The PGA-based capsule in B. anthracis is a major virulence
factor due to its antiphagocytic property (38).
In B. anthracis, CapB and CapC are believed to form a tight
membrane-associated complex to catalyze the synthesis of
PGA (4), whereas CapA is suggested to be a transporter (3).
We named FTL_1414 CapA based on its predicted transporter
function as a putative transmembrane protein, although
FTL_1414 does not resemble any of the B. anthracis capsule
genes. CapD, -glutamyltranspeptidase, is required for the co-
valent attachment of the B. anthracis capsule to the cell wall
peptidoglycan (7). An ortholog of the B. anthracis CapD exists
elsewhere in the F. tularensis LVS genome (FTL_0766), al-
though this screening did not identify a capD mutant.
The PGA-based capsule has been identified in only a few
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gram-positive bacteria, such as B. anthracis and Staphylococcus
epidermidis (37). However, recent genome sequencing studies
have also revealed orthologs for PGA biosynthesis genes in
several other gram-negative bacteria, including Idiomarina bal-
tica (35), Rhodopirellula baltica (27), Leptospira interrogans
(57), Oceanobacillus iheyensis (68), and Desulfitobacterium
hafniense (51). It is intriguing that these bacteria, along with F.
tularensis, are all associated with water environments. As rep-
resented in Fig. 3, the capBCA genes of F. tularensis are also
similar to the putative PGA biosynthetic genes in these bacte-
ria (Fig. 3). The capBCA and capD genes found in LVS are
also conserved in other F. tularensis strains, including OSU18
(accession no. CP000437) (54) and Schu S4 (accession no.
AJ749949) (40).
We confirmed the attenuation of the mutants with disrup-
tions in the capBCA locus by coinfection experiments. As
shown in Table 2, the representative transposon mutants in
capB (strain JS2512), capC (strain JS2531), and capA (strain
JS4622) were out-competed by the parent strain in the lung
infection model. The capB and capC mutants (JS2512 and
JS2531) were completely undetectable in all three infected
mice 7 days postinfection; the capA mutant (JS4622) was de-
tectable in two of the three infected mice. These mutants were
also compared with the parent strain LVS by separately infect-
ing mice with individual mutants. Seven days post-intranasal
inoculation, the mice infected with strain JS2512 (capB),
JS2531 (capC), or JS4622 (capA) had a 1,000-fold reduction
in the bacterial burden in the lungs compared with those in-
fected with LVS (data not shown).
To exclude the possibility that the attenuation of these trans-
poson mutants was due to possible transposon insertions else-
where in the LVS genome, we constructed deletion mutants in
the capBCA locus. The coding sequences of the capBCA genes
were deleted by allelic replacement as illustrated in Fig. 4. The
deletion mutants were characterized by PCR amplification of
the capBCA locus using the flanking sequence-based primers
and DNA sequencing. As a result, the entire coding sequences
of capB, capC, and capA except for the 5 capB (29-bp) and 3
capA (82-bp) regions were deleted in frame from the LVS
chromosome by unmarked deletion. While the wild-type strain
LVS showed a 3.4-kb PCR product, ST938, one of the con-
firmed capBCA deletion mutants yielded a PCR fragment with
an expected size of 643 bp (Fig. 4A) and correct sequence
(data not shown). Consistent with the transposon insertion
mutants in the capBCA locus (Table 1), ST938 did not show a
significant growth defect in MHB (Fig. 4B). We also wanted to
generate an in trans complementation construct with the entire
capBCA operon. All attempts with different shuttle plasmids
yielded either partial or no inserts, suggesting that capBCA
expression in E. coli may be toxic.
We compared ST938 with LVS in terms of their in vivo
survival in mice. Consistent with the results obtained with
FIG. 3. In trans complementation of the capB and capC disruptive mutants. (A) Genetic organization of the capBCA locus in LVS. The genes
and their coding directions are represented with open arrows and arrowheads, respectively. The transposon insertion sites of the capB (JS2512)
and capC (JS2531) mutants are indicated with vertical arrowheads. The numbers of intergenic nucleotides are indicated at the bottom. (B) Gen-
eration of complementation constructs in plasmid pMP633. The wild-type capB and capC genes of LVS were inserted into the NdeI site of pMP633.
(C) Bacterial load in lungs of mice infected with LVS and isogenic transposon mutants. BALB/c mice were intranasally infected with strains LVS
(12,400 CFU/mouse), JS2512 (capB mutant; 30,840 CFU/mouse), JS2531 (capC mutant; 28,000 CFU/mouse), capB-complemented JS2512 (34,000
CFU/mouse), and capC-complemented JS2531 (30,000 CFU/mouse). The bars represent the mean CFU values  standard errors of bacterial
levels in the lungs of three mice 7 days postinfection. P values were determined based on comparisons of the values between the transposon mutants
and corresponding in trans-complemented strains using Student’s t test in Microsoft Excel.
VOL. 75, 2007 FRANCISELLA TULARENSIS VIRULENCE FACTORS 3097
multiple transposon mutants in the capBCA locus (Table 2),
the bacterial load in the lungs of the ST938-infected mice was
1,697-fold lower than the mean CFU value obtained with the
LVS-infected mice 7 days postinfection (Fig. 4C). The capBCA
mutant strain also showed significantly reduced levels of
overall bacterial burden in other tissue sites. When com-
pared with the LVS-infected mice, the bacterial loads in the
livers and spleens of the ST938-infected mice were de-
creased by 241- and 7.3-fold, respectively (Fig. 4C). Finally,
all 12 mice infected with ST938 survived throughout the
3-week infection experiments, whereas all of the mice in-
fected with a similar dose of LVS died in the first 2 weeks
postinfection (data not shown). These results demonstrate that
the capBCA locus is critical for in vivo replication/survival and
virulence of F. tularensis.
DISCUSSION
This study represents the first extensive search of F. tularen-
sis virulence determinants by completing an STM study in a
respiratory infection mouse model. We have identified a total
of 95 genes required for the survival of LVS in the lungs of
mice. All but 2 of the 95 genes identified in LVS are present in
the fully sequenced genomes of other F. tularensis strains,
including OSU18 (54) and Schu S4 (40). It is thus reasonable
to expect that at least some of the factors identified in this
study, if not all, are important for the pathogenic process of
fully virulent F. tularensis strains. The majority of the genes
identified in this study, including the capBCA locus, are also
present in the recently released genome of F. tularensis subsp.
novicida strain U112 (GenBank accession no. CP000439).
Strain U112 has been commonly used to identify most of the
known F. tularensis virulence factors, including the intracellu-
lar growth iglABCD locus (24, 31, 42, 71). These findings are
consistent with the highly conserved genetic contents among
various F. tularensis subspecies as revealed by recent genomic
studies (40, 54). Our findings along with other studies argue
that the genetic basis of F. tularensis adaptation and virulence
is highly similar among different subspecies; it is perhaps the
minor genetic variations and/or epigenetic differences among
different F. tularensis subspecies and strains that determine the
outcome of infection in various mammalian hosts. This inves-
FIG. 4. Construction and characterization of the capBCA deletion mutant. (A) Construction of the deletional mutation in the capBCA locus.
The sequences flanking the capBCA genes were separately amplified and cloned in the SacI/XhoI-digested pDMK plasmid. The resulting plasmid
was introduced into LVS by conjugation. Following sequential selection steps with kanamycin and sucrose, the resultant strains (as represented
by strain ST938) were examined for loss of the capBCA genes by PCR. The sizes of the representative molecular markers (M) are indicated in kb.
Approximate locations of the relevant primers are marked with small lateral arrows. (B) Growth of the capBCA deletion mutant in MHB. LVS
and ST938 were separately cultured in 5 ml MHB. Optical absorbance levels (OD600) were determined for each culture at the indicated time points.
The value represents the means  standard errors of five independent cultures. (C) Bacterial load in mice infected with the capBCA deletion
mutant ST938 (6,500 CFU/mouse) and LVS (4,000 CFU/mouse). BALB/c mice were intranasally infected with ST938 or LVS and sacrificed 7 days
later to determine bacterial levels in the lungs, livers, and spleens. The bars represent the mean CFU values  standard errors of six mice. Asterisks
indicate P 
 0.05 as determined using Student’s t test in Microsoft Excel.
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tigation has greatly expanded current knowledge regarding the
genetic basis of F. tularensis virulence.
Some of the genes identified in this study have been previ-
ously implicated as virulence determinants of F. tularensis by
other investigators. Included among those are MinD (1), ClpB
(31, 71), the intracellular growth locus (31, 39, 63), and the LPS
O-antigen biosynthesis locus (12, 56, 72). This study has also
revealed a large list of novel F. tularensis genes that are re-
quired for in vivo survival. Consistent with previous STM stud-
ies in other pathogens (10), this STM analysis has identified a
number of genes that are involved in basic metabolism and
physiology. Impaired growth in vivo might be the cause for the
attenuation of some mutants in this category. In a strict sense,
the genes involved in basic metabolism and physiology should
not be regarded as virulence factors (9). However, the infor-
mation along this line can be valuable for treatment and pre-
vention of tularemia. The metabolic genes identified in this
study may be targeted for future development of therapeutic
agents. In particular, the attenuated strains of metabolic genes
can be used to develop genetically defined vaccines against
virulent F. tularensis strains.
A significant number of the genes identified in this study
have apparent functions in intracellular growth/survival of the
bacterium. Besides the intracellular growth locus (iglABCD),
the identified proteases/chaperones (ClpB, ClpXP, Lon, and
Tig) are particularly interesting in the context of in vivo adap-
tation of F. tularensis to various stress conditions. These con-
served proteins are required for protein folding and/or degra-
dation in many bacteria (6, 30). Recent studies have
demonstrated that F. tularensis is able to survive in the phago-
somes of macrophages and replicate in cytoplasm (62). It is
reasonable to believe that these proteases/chaperones may
promote the survival and replication of F. tularensis in mam-
malian hosts by refolding misfolded proteins and removing the
damaged proteins or normal proteins that become unnecessary
or detrimental to the bacterium under certain stress condi-
tions. Mpa, a Clp-like protease in the proteasome of Mycobac-
terium tuberculosis, has been demonstrated to be necessary for
bacterial resistance to nitric oxide and growth in macrophages
(14, 15). Identification of attenuated mutants with insertions in
the genes encoding catalase (katG), DNA repair enzyme
(uvrA), and cold shock protein (deaD) further supports the
notion that stress-relieving mechanisms are critical for F. tula-
rensis adaptation in mammalian hosts. Our data now provide
specific genetic targets for further understanding of the mo-
lecular basis of F. tularensis adaptation in different host niches
and various stages of infection.
Many attenuated mutants carried transposon insertions in
the genes associated with bacterial cell surface structures (e.g.,
membrane proteins, LPS, and capsule). The genes in this cat-
egory are particularly interesting because the encoded prod-
ucts may be involved in pathogen-host interactions and may
also represent potential targets for future development of ther-
apeutics and subunit vaccines. A subset of the mutants con-
tained insertions in the genes encoding putative lipoproteins,
outer membrane proteins, and transmembrane proteins. Ex-
cept for FopA (FTL_1328) and Tul4 (FTL_0421), none of
these proteins has been previously described. FopA, a heat-
modifiable outer membrane-associated protein (49), is re-
quired for the growth of F. tularensis subsp. novicida in murine
macrophages (71). Tul4 was originally identified as a 17-kDa
T-cell-stimulating lipoprotein in LVS (65, 66). A recent
TnphoA screening study identified six exported F. tularensis
proteins (26), but these proteins do not match any of the putative
membrane proteins identified in this study. This screening also
identified wbtA (FTL_0592) and wbtF (FTL_0597), two genes
encoding enzymes for modifying the LPS O-antigen. Consistent
with our finding, other studies have implicated LPS as an essential
surface structure for F. tularensis immune evasion and serum
resistance (12, 32, 56, 70, 72).
We have identified a putative capsule locus in LVS which
partially resembles the well-characterized capsule biosynthetic
genes in B. anthracis. Bacterial capsules, the outermost struc-
ture of the bacterial surfaces, can provide a selective advantage
by preventing desiccation in the environment and, for patho-
gens, by promoting adherence and conferring resistance to
host defense mechanisms, such as complement-mediated
phagocytosis and killing. The pXO2 plasmid-encoded B. an-
thracis capsule is a key antiphagocytic virulence factor (38). A
capsule has been revealed for fully virulent F. tularensis strains
by electron microscopy, although it is readily removed upon
hypertonic treatment or aerosolization (34, 60, 67). The cap-
sule is a key virulence factor based on the observations that
unencapsulated bacteria are more susceptible to complement-
mediated killing (60) and are avirulent (34). The capsule ap-
pears to contain large amounts of lipid, but other components
are unknown (34). The sequence similarity between the F.
tularensis capBCA genes and the capsular biosynthesis genes of
other bacteria suggests the production of PGA in F. tularensis.
The mouse infection experiments with various mutants of the
capBCA locus consistently demonstrated that these genes are
essential for in vivo survival and virulence of F. tularensis. A
PGA-based capsule has only been reported in gram-positive
bacteria (Bacillus and Staphylococcus species), although se-
quence information has suggested that PGA is produced in
multiple gram-negative species (8). The identification of the
capBCA locus as a virulence determinant of F. tularensis has
provided ample reason for further characterization of this lo-
cus. Future characterization of the F. tularensis capBCA locus
will also be instrumental for determining whether PGA is a
constituent of the capsule in gram-negative bacteria.
All but two genetic loci identified in LVS are conserved in
the other F. tularensis strains, OSU18 and Schu S4, in terms of
predicted amino acid sequence and the local gene order. Our
study has thus provided a genetic basis for further character-
ization of the pathogenic mechanisms of F. tularensis strains
that are fully virulent for humans. FTL_1134 and FTL_0439
represent two LVS-specific genetic loci identified in this
screening. FTL_1134, a hypothetical membrane protein, is en-
tirely absent in the Schu S4 genome. FTL_0439 represents a
fusion product of two Schu S4 genes (FTT0918 and FTT0919).
A previous study showed that mutations in FTT0918 abolished
the virulence of strain Schu S4 in mice (73). It is possible that
FTL_0439 and FTT0918 share a common function in terms of
enhancing in vivo survival of F. tularensis. A significant number
of the F. tularensis genes represented by the attenuated mu-
tants cannot be matched with apparent function. Among these
are F. tularensis-specific genes and the genes with uncharacter-
ized orthologs in other bacteria. Future characterization of
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these “unknown” genes may be fruitful in terms of understand-
ing the pathogenic mechanisms that are unique to F. tularensis.
After our STM screening was completed, other investigators
observed that the promoter driving the kanamycin resistance
gene in the EZ::TN transposon is inactive in F. tularensis (24,
46). This implies that the recovery of the F. tularensis transpo-
son mutants under in vitro culture conditions requires active
transcription of the target genes. Consistent with this, reexam-
ination of our sequence data for the attenuated STM strains
revealed that the kanamycin resistance gene was always orien-
tated in the same direction as the target genes in the LVS
chromosome. On one hand, these lines of information have
highlighted the limitations of our mutagenesis approach in
identifying virulence determinants. It is thus clear that our
STM screening has missed those virulence-associated genes
whose promoter activities did not support the kanamycin re-
sistance. On the other hand, the information from this unin-
tended “bias” has provided some important information on the
biology of F. tularensis. Our data indicate that the F. tularensis
genes identified in this study are actively expressed under both
in vitro and in vivo conditions. There is a shortage of well-
characterized promoter elements that can drive gene expres-
sion in F. tularensis under various conditions. We have thus
provided many F. tularensis promoters that can drive gene
expression in F. tularensis under culture and infection condi-
tions.
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